In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés ...

Pharmacogenomics (PGx) is the study of how genetic variation affects the efficacy and safety of medicines, enabling ...

Analysis of Trump’s ‘Most Favoured Nation’ Executive Order on drug pricing, its global impact, price convergence aims, and ...

New OHE insight on immunisation: despite high returns on investment, global spending lags. We outline why and how countries ...

With over 60 years of expertise, the Office of Health Economics (OHE) is the world’s oldest independent health economics research organisation. We are a registered charity and an Independent Research ...

Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised. The world is currently undergoing significant ...

To help inform the current debate on assisted dying, we have updated the findings of our 2019 palliative report with the latest data. A previous OHE report in 2019 estimated that 378, 427 people in ...

This publication provides both up-to-date statistics and a guide to finding and using health statistics from the UK and, to some extent, other OECD countries. Data are presented in easy-to-read tables ...

OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs). In addition to ...